author-photo

Simon Smith

AstraZeneca

23

Papers

135

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

2018 Clinical and Translational Radiation Oncology
Show All
- Source
- Cite
- Save
Citations (38)